Abstract

AdaptHealth Corp. will report first-quarter results on May 05, 2026 Pre-Market; this preview compiles consensus forecasts, last quarter’s performance, business segment dynamics, and the dominant analyst view to frame what matters for the print and the stock’s near-term direction.

Market Forecast

Consensus points to revenue of 796.62 million US dollars for the quarter, implying 4.17% year-over-year growth, with EBIT near 26.09 million US dollars (down 24.66% year-over-year) and EPS around $0.02 (up 328.50% year-over-year from a low base). No explicit market forecast for gross profit margin or net margin is available, though the mix and investment cadence suggest a modestly improving earnings trajectory off last quarter’s trough.

The core business remains paced by sleep therapy and respiratory categories, where patient adherence programs and resupply execution are likely to support steady volumes and mix resilience through 2026. Diabetes supplies appears positioned as the most promising segment given the ramp of value-based arrangements; last quarter it contributed roughly 154.48 million US dollars, and its near-term growth is expected to track within the company’s 2026 organic growth framework of about 7.5%–9.5% year-over-year as implementation progresses.

Last Quarter Review

AdaptHealth Corp. reported revenue of 846.29 million US dollars, a gross profit margin of 21.85%, GAAP net loss attributable to common shareholders of 103.00 million US dollars, a net profit margin of -12.14%, and adjusted EPS of $0.19, with total revenue down 1.21% year-over-year and adjusted EPS down 44.12% year-over-year.

The quarter registered a sharp sequential deterioration in GAAP profit (quarter-on-quarter change in net profit of -519.32%), with revenue beating consensus by 14.68 million US dollars but adjusted EPS underperforming a $0.35 consensus. Sleep therapy devices drove the mix at roughly 359.02 million US dollars of last quarter’s revenue (around 42.47% of the total) in a period when company-level revenue fell 1.21% year-over-year, reflecting operational outlays and a demanding comparison base.

Current Quarter Outlook

Main Business Momentum: Sleep Therapy and Respiratory

The quarter-to-date setup for sleep therapy and respiratory suggests stable volume support from patient resupply and new patient onboarding initiatives, with incremental gains from adherence programs and software-enabled workflows that drive order accuracy and reimbursement timing. The segment mix leans toward recurring resupply revenue, which typically dampens volatility in consumption patterns and supports cash conversion, a theme that is especially relevant following the sequential GAAP loss last quarter. In this context, cost control in logistics and branch operations, alongside tighter procurement for devices and supplies, becomes a primary lever to sustain a gross profit margin recovery path from the 21.85% level reported in the prior period.

Management’s focus on operational discipline is likely to show up most clearly in the gap between revenue growth and EBIT, as the prior quarter’s EBIT turned negative while the current quarter’s forecast implies a positive 26.09 million US dollars—evidence of cyclical margin normalization after a heavy spend phase. The market’s reliance on $0.02 of EPS implies a restrained operating margin profile this quarter, but even modest resupply and patient growth can translate disproportionately to earnings when back-office automation and order capture improvements compound. Given the contribution from sleep therapy devices in the fourth quarter (approximately 359.02 million US dollars), holding mix around this range while preventing leakage in denials and write-offs can be sufficient to meet or beat revenue without requiring aggressive pricing or unusual one-offs.

From a cash standpoint, working capital discipline around inventory turns and durable equipment utilization can provide an additional offset to elevated labor and distribution costs. If the company can show improved claims cycle time and stabilization in device sourcing costs, incremental gross profit dollars from the sleep therapy and respiratory categories should convert at a higher rate to operating income, lending upside to the EBIT consensus even if reported gross margin remains near the low-20s percentage range.

Most Promising Business: Diabetes Supplies and Value-Based Arrangements

Diabetes supplies, including continuous glucose monitoring and related consumables, appears set for faster growth relative to the corporate average as the company ramps value-based and capitated arrangements with payors. Last quarter, diabetes supplies accounted for roughly 154.48 million US dollars of revenue, and external commentary indicates that investment to prepare for capitated contract implementation—staffing, vehicles, and equipment—was front-loaded. That near-term spend dynamic points to a temporary EBIT headwind, but it also materially raises the capacity ceiling for 2026 volumes and services per patient.

Expectations for the current quarter are that diabetes supplies growth will gravitate toward the company’s 2026 organic revenue growth plan of about 7.5%–9.5% year-over-year as operational readiness converts into billed activity and as adherence tools keep patients on therapy. Even modest increases in device placements and supply reorder frequency can produce strong dollar growth in this segment because the revenue base is already sizable and relatively recurring. Key execution markers to watch in the print include commentary on patient adds under capitated structures, contract-level service scope, and per-patient economics that inform how quickly revenue can outpace incremental operating expense.

From an earnings sensitivity perspective, diabetes supplies has potential to compress or expand gross margin depending on product and payer mix in any given quarter; scaled purchasing and routing optimization can mitigate that volatility. If management demonstrates that March run-rate metrics improved versus January and February, and if early readouts from capitated cohorts show planned utilization patterns, investors are likely to extrapolate a stronger second-half trajectory. That would justify the current consensus of 4.17% year-over-year revenue growth for the quarter and strengthen the case for progressive EPS improvement beyond the $0.02 implied for this print.

Stock Price Drivers This Quarter

The most direct near-term driver is the relationship between top-line delivery and expense containment after the fourth quarter’s loss: a revenue outcome at or above 796.62 million US dollars, paired with evidence of expense normalization, would validate the EBIT swing back to a positive 26.09 million US dollars and support the view that last quarter’s trough was transient. A second driver is the cadence of gross margin improvement; even a fractional move off 21.85% toward the mid-20s over the coming quarters—supported by better sourcing, denial prevention, and a richer mix of high-attach consumables—would materially improve earnings power without requiring outsized revenue growth.

Balance sheet perception is the third important driver. On January 27, 2026, Moody’s upgraded the company’s ratings to Ba2 for the corporate family and B1 for senior unsecured notes, reflecting progress in debt reduction and financial flexibility. A lower cost of debt and better access to capital improve the company’s ability to support value-based initiatives and absorb ramp costs, which, in turn, influences the market’s willingness to underwrite an EPS recovery after the fourth quarter’s GAAP loss. If the company can report healthy cash generation and point to further deleveraging plans, the rating trajectory becomes part of the equity narrative—bolstering confidence in the sustainability of any rebound in EPS through 2026.

The final near-term stock catalyst is guidance language. While the market already has a full-year 2026 revenue range from recent communications, investors will focus on whether quarterly commentary implies a back-half weighting as the capitated program ramps. If management confirms that early-year investments were front-loaded and that second-half mix and utilization favor margin expansion in diabetes supplies while sleep therapy and respiratory remain steady, the stock reaction is likely to key off that slope rather than off small absolute deltas to the $0.02 EPS line.

Analyst Opinions

The prevailing view is bullish. Among the tracked notes in the period from January 2026 to April 2026, bullish opinions account for 100% with no bearish calls in the sample. On February 26, 2026, RBC Capital Markets argued that the shares appeared oversold following the fourth quarter’s softer results and emphasized optimism about the long-term value of the new capitated contract and the potential for additional value-based care arrangements; the note highlighted management’s early actions—hiring, vehicle purchases, and equipment acquisition—to derisk implementation. On April 13, 2026, Truist raised its price target to 14.00 US dollars from 13.00 US dollars while maintaining a Buy, reflecting confidence in execution through 2026 and alignment with the company’s organic growth plan. The broader takeaway from these opinions is that the investment required to stand up capitated contracts may weigh on near-term profitability, but that the unit economics and service scope should support revenue expansion and earnings normalization as the program scales.

The bullish camp’s core reasoning leans on three pillars. First, revenue resilience is supported by recurring resupply in sleep therapy and consumables, reducing the need for outsized patient growth to meet the quarter’s 4.17% year-over-year target. Second, the capitated strategy in diabetes supplies is expected to accelerate top-line growth and improve patient lifetime value, with near-term investments designed to execute at scale rather than to temporarily inflate revenue. Third, credit-quality upgrades, such as the Moody’s move to Ba2 on January 27, 2026, reinforce the balance sheet trajectory and reduce the equity risk premium while the company transitions to value-based revenue streams.

In terms of what analysts want to see in the print, there is a preference for proof points that margin pressure is stabilizing and that the EBIT consensus of 26.09 million US dollars is achievable without nonrecurring tailwinds. Commentary around claims processing times, equipment procurement costs, and resupply adherence rates will be scrutinized as leading indicators. Should management demonstrate sequential improvement in these metrics and provide a confident pacing update for capitated contracts, the bullish majority expects the stock to respond positively, particularly if management also reiterates full-year revenue targets consistent with the 7.5%–9.5% organic growth framework for 2026.